Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 871 to 880 of 1331 total matches.

Candesartan for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Nov 20, 1998  (Issue 1040)
hydrolyzed to its active metabolite candesartan, reaching peak plasma concentrations in three to four hours ...
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.
Med Lett Drugs Ther. 1998 Nov 20;40(1040):109-10 |  Show IntroductionHide Introduction

Growth-Hormone-Releasing-Factor for Growth Hormone Deficiency

   
The Medical Letter on Drugs and Therapeutics • Jan 01, 1999  (Issue 1043)
have full biological activity. Administration of GHRH in repeated boluses stimulates release of growth ...
Sermorelin acetate, a synthetic form of human growth-hormone-releasing factor has been approved by the FDA for treatment of idiopathic growth hormone deficiency in children with growth failure.
Med Lett Drugs Ther. 1999 Jan 1;41(1043):2-3 |  Show IntroductionHide Introduction

Miglitol for Type 2 Diabetes Mellitus

   
The Medical Letter on Drugs and Therapeutics • May 21, 1999  (Issue 1053)
diminish with time. Increased aminotransferase activity has not been reported with miglitol. Low serum ...
Miglitol, an oral alpha-glucosidase inhibitor similar to acarbase, is now available for treatment of type 2 diabetes.
Med Lett Drugs Ther. 1999 May 21;41(1053):49-50 |  Show IntroductionHide Introduction

A New Conjugated Estrogen

   
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999  (Issue 1058)
or uterine cancer, women with undiagnosed vaginal bleeding, active thrombophlebitis or thromboembolic ...
A new synthetic conjugated estrogen product (Cenestin - Duramed) was recently approved by the US Food and Drug Administration for treatment of vasomotor symptoms due to estrogen deficiency.
Med Lett Drugs Ther. 1999 Jul 30;41(1058):67-70 |  Show IntroductionHide Introduction

Malathion for the Treatment of Head Lice

   
The Medical Letter on Drugs and Therapeutics • Aug 13, 1999  (Issue 1059)
, 1998; HR Contreras and E Bustos-Obregón, J Exp Zool, 284:355, 1999). ACTIVITY — Malathion 0.5 ...
0.5% malathion in 78% isopropanol was recently approved by the FDA for treatment of head lice.
Med Lett Drugs Ther. 1999 Aug 13;41(1059):73-4 |  Show IntroductionHide Introduction

Cevimeline (Evoxac) For Dry Mouth

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000  (Issue 1084)
of antimuscarinic drugs such as atropine or scopolamine. Patients with poor CYP2D6 activity may have a higher risk ...
Cevimeline hydrochloride, an acetylcholine derivative, has been approved by the FDA for treatment of dry mouth symptoms caused by Sjogren's syndrome. Presumably it could also be used to treat radiation-induced xerostomia in patients with head and neck cancer. Pilocarpine hydrochloride is FDA-approved for both indications
Med Lett Drugs Ther. 2000 Aug 7;42(1084):70 |  Show IntroductionHide Introduction

Eflornithine Cream For Facial Hair Reduction

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000  (Issue 1089)
procedures were needed less frequently. The difference between the active drug and placebo was detectable ...
Eflornithine hydrochloride cream 13.9% (Vaniqa - Bristol-Myers Squibb) has been approved by the FDA for reduction of unwanted facial hair in women.
Med Lett Drugs Ther. 2000 Oct 2;42(1089):96 |  Show IntroductionHide Introduction

Ortho Evra - A Contraceptive Patch

   
The Medical Letter on Drugs and Therapeutics • Jan 21, 2002  (Issue 1122)
mg of the progestin norelgestromin (the active metabolite of norgestimate) and 0.75 mg of ethinyl ...
A transdermal contraceptive patch (Ortho Evra — Ortho-McNeil) has been approved by the FDA. Each 20 cm2 patch contains 6 mg of the progestin norelgestromin (the active metabolite of norgestimate) and 0.75 mg of ethinyl estradiol.
Med Lett Drugs Ther. 2002 Jan 21;44(1122):8 |  Show IntroductionHide Introduction

Anakinra (Kineret) For Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 18, 2002  (Issue 1124)
of moderately to severely active rheumatoid arthritis in adults who have failed at least one disease-modifying ...
Anakinra (Kineret - Amgen), an interleuken-1 (IL-1) receptor antagonist, has been approved by the FDA for treatment of moderately to severly active rheumatoid arthritis in adults who have failed at least one disease-modifying anti-rheumatic drug(DMARD) such as methotrexate (Medical Letter 2000; 24:57).
Med Lett Drugs Ther. 2002 Feb 18;44(1124):18-9 |  Show IntroductionHide Introduction

Ophthalmic Cyclosporine (Restasis) for Dry Eyes

   
The Medical Letter on Drugs and Therapeutics • May 26, 2003  (Issue 1157)
cyclosporine have shown reduced numbers of activated lymphocytes, decreased levels of inflammatory cytokines ...
A cyclosporine 0.05% ophthalmic emulsion (Restasis - Allergan) has been approved by the FDA for use in patients with dry eye disease (keratoconjunctivitis sicca). This review begins with a discussion of the causes of dry eye disease and includes sections on the pharmacology, adverse effects and clinical trial results for ophthalmic cyclosporine. Cost information and recommendations for administering the drug are also presented. The review concludes with an overall assessment of the drug's efficacy, safety and cost.
Med Lett Drugs Ther. 2003 May 26;45(1157):42-3 |  Show IntroductionHide Introduction